Home › Trial NCT00209989
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
- Trial IDNCT00209989
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorInstitut Claudius Regaud
- Enrollment27
- Start date2005-10
- ConditionsGlioblastoma Multiforme
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.